{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:32:43Z","timestamp":1791232363434,"version":"4.1.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1016\/j.iac.2006.05.003","type":"journal-article","created":{"date-parts":[[2007,1,10]],"date-time":"2007-01-10T15:09:23Z","timestamp":1168441763000},"page":"575-592","source":"Crossref","is-referenced-by-count":41,"title":["KIT Mutations in Mastocytosis and Their Potential as Therapeutic Targets"],"prefix":"10.1016","volume":"26","author":[{"given":"Jason","family":"Gotlib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.iac.2006.05.003_bib1","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1002\/j.1460-2075.1987.tb02655.x","article-title":"Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand","volume":"11","author":"Yarden","year":"1987","journal-title":"EMBO J"},{"issue":"4","key":"10.1016\/j.iac.2006.05.003_bib2","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1046\/j.0007-1048.2001.03294.x","article-title":"Class III receptor tyrosine kinases: role in leukaemogenesis","volume":"116","author":"Reilly","year":"2002","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.iac.2006.05.003_bib3","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.20.6.1692","article-title":"Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies","volume":"20","author":"Heinrich","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.iac.2006.05.003_bib4","doi-asserted-by":"crossref","unstructured":"Rousset D, Agnes F, Lachaume P, et\u00a0al. Molecular evolution of the genes encoding receptor tyrosine kinase with immunoglobulin-like domains. J Mol Evol 1995;41(4):421\u20139.","DOI":"10.1007\/BF00160313"},{"issue":"1","key":"10.1016\/j.iac.2006.05.003_bib5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.174.1.63","article-title":"Expression and function of c-kit in hemopoietic progenitor cells","volume":"174","author":"Ogawa","year":"1991","journal-title":"J Exp Med"},{"issue":"22","key":"10.1016\/j.iac.2006.05.003_bib6","first-page":"6139","article-title":"Expression of c-kit receptor in normal and transformed human nonlymphoid tissues","volume":"52","author":"Natali","year":"1992","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.iac.2006.05.003_bib7","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1101\/gad.3.6.816","article-title":"Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice\u2014evidence for an impaired c-kit kinase in mutant mice","volume":"3","author":"Nocka","year":"1989","journal-title":"Genes Dev"},{"issue":"6512","key":"10.1016\/j.iac.2006.05.003_bib8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/373347a0","article-title":"W\/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity","volume":"373","author":"Huizinga","year":"1995","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.iac.2006.05.003_bib9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0092-8674(90)90297-R","article-title":"Identification of a ligand for the c-kit proto-oncogene","volume":"63","author":"Williams","year":"1990","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.iac.2006.05.003_bib10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0092-8674(90)90302-U","article-title":"Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor","volume":"63","author":"Zsebo","year":"1990","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.iac.2006.05.003_bib11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0092-8674(90)90303-V","article-title":"The hematopoietic growth factor KL is encoded by the SI locus and is the ligand of the c-kit receptor, the gene product of the W locus","volume":"63","author":"Huang","year":"1990","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.iac.2006.05.003_bib12","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1357-2725(99)00078-3","article-title":"Early signaling pathways activated by c-Kit in hematopoietic cells","volume":"31","author":"Linnekin","year":"1999","journal-title":"Int J\u00a0Biochem Cell Biol"},{"issue":"24","key":"10.1016\/j.iac.2006.05.003_bib13","doi-asserted-by":"crossref","first-page":"16965","DOI":"10.1074\/jbc.274.24.16965","article-title":"STAT protein recruitment and activation in c-Kit deletion mutants","volume":"274","author":"Brizzi","year":"1999","journal-title":"J Biol Chem"},{"issue":"5350","key":"10.1016\/j.iac.2006.05.003_bib14","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors","volume":"279","author":"Hirota","year":"1998","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.iac.2006.05.003_bib15","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0002-9440(10)64946-2","article-title":"KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors","volume":"156","author":"Lux","year":"2000","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.iac.2006.05.003_bib16","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1046\/j.1365-2141.1999.01449.x","article-title":"c-Kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia","volume":"105","author":"Gari","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.iac.2006.05.003_bib17","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V95.2.726","article-title":"C-Kit mutations in core binding factor leukemias","volume":"95","author":"Beghini","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.iac.2006.05.003_bib18","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S0002-9440(10)65419-3","article-title":"Activating c-kit gene mutations in human germ cell tumors","volume":"154","author":"Tian","year":"1999","journal-title":"Am J Pathol"},{"issue":"9","key":"10.1016\/j.iac.2006.05.003_bib19","first-page":"2345","article-title":"Specific c-kit mutations in sinonasal natural killer\/T-cell lymphoma in China and Japan","volume":"60","author":"Hongyo","year":"2000","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.iac.2006.05.003_bib20","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1172\/JCI116761","article-title":"Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product","volume":"92","author":"Furitsu","year":"1993","journal-title":"J Clin Invest"},{"issue":"23","key":"10.1016\/j.iac.2006.05.003_bib21","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.iac.2006.05.003_bib22","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng0396-312","article-title":"Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm","volume":"12","author":"Longley","year":"1996","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.iac.2006.05.003_bib23","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis","volume":"96","author":"Longley","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.iac.2006.05.003_bib24","first-page":"46","article-title":"Chronic myelogenous leukemia and myeloproliferative disease","volume":"1","author":"O'Brien","year":"2004","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"1","key":"10.1016\/j.iac.2006.05.003_bib25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000085563","article-title":"Clonality and molecular pathogenesis of mastocytosis","volume":"114","author":"Akin","year":"2005","journal-title":"Acta Haematol"},{"issue":"5","key":"10.1016\/j.iac.2006.05.003_bib26","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.V98.5.1365","article-title":"Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-KIT mutant","volume":"98","author":"Chian","year":"2001","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.iac.2006.05.003_bib27","first-page":"4412","article-title":"Phosphatidylinositol 3\u2032-kinase is required for growth of mast cells expressing Kit catalytic domain mutant","volume":"63","author":"Shivakrupa","year":"2003","journal-title":"Cancer Res"},{"issue":"25","key":"10.1016\/j.iac.2006.05.003_bib28","doi-asserted-by":"crossref","first-page":"14665","DOI":"10.1073\/pnas.93.25.14665","article-title":"Oncogenic mutation in the KIT receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1","volume":"93","author":"Piao","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1016\/j.iac.2006.05.003_bib29","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0145-2126(01)00028-5","article-title":"Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy","volume":"25","author":"Longley","year":"2001","journal-title":"Leuk Res"},{"issue":"41","key":"10.1016\/j.iac.2006.05.003_bib30","doi-asserted-by":"crossref","first-page":"38627","DOI":"10.1074\/jbc.M204890200","article-title":"Definition of an inhibitory juxtamembrane WW-like domain in the platelet-derived growth factor beta receptor","volume":"277","author":"Irusta","year":"2002","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.iac.2006.05.003_bib31","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2003-06-1824","article-title":"The FIP1L1-PDGFR\u03b1 fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management","volume":"103","author":"Gotlib","year":"2004","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.iac.2006.05.003_bib32","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.iac.2006.05.003_bib33","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.iac.2006.05.003_bib34","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.iac.2006.05.003_bib35","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.iac.2006.05.003_bib36","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.iac.2006.05.003_bib37","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1200\/JCO.2002.01.027","article-title":"Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans","volume":"20","author":"Rubin","year":"2002","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.iac.2006.05.003_bib38","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"issue":"5607","key":"10.1016\/j.iac.2006.05.003_bib39","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1126\/science.1079666","article-title":"PDGFRA activating mutations in gastrointestinal stromal tumors","volume":"299","author":"Heinrich","year":"2003","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.iac.2006.05.003_bib40","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.iac.2006.05.003_bib41","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/sj.onc.1206120","article-title":"Effect of the tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms","volume":"22","author":"Zermati","year":"2003","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.iac.2006.05.003_bib42","first-page":"1115","article-title":"Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant","volume":"1","author":"Frost","year":"2002","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.iac.2006.05.003_bib43","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","article-title":"Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit","volume":"31","author":"Akin","year":"2003","journal-title":"Exp Hematol"},{"issue":"9383","key":"10.1016\/j.iac.2006.05.003_bib44","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","article-title":"Imatinib for systemic mast-cell disease","volume":"362","author":"Pardanani","year":"2003","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.iac.2006.05.003_bib45","first-page":"918a","article-title":"Treatment-relevant molecular classification of systemic mast cell disease associated with eosinophilia","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.iac.2006.05.003_bib46","first-page":"335b","article-title":"Imatinib seems to be ineffective in patients with systemic mastocytosis carrying the Asp816Val c-kit mutation","volume":"102","author":"Rondoni","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.iac.2006.05.003_bib47","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ajh.20211","article-title":"Management of patients with systemic mastocytosis: review of the M.D. Anderson Cancer Center Experience","volume":"77","author":"Hennessy","year":"2004","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.iac.2006.05.003_bib48","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.leukres.2003.09.001","article-title":"Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis","volume":"28","author":"Musto","year":"2004","journal-title":"Leuk Res"},{"issue":"11","key":"10.1016\/j.iac.2006.05.003_bib49","doi-asserted-by":"crossref","first-page":"271b","DOI":"10.1182\/blood.V104.11.4752.4752","article-title":"Imatinib mesylate for patients (pts) with hypereosinophilic syndrome (HES) and systemic mastocytosis (SM): a phase II trial","volume":"104","author":"Jabbour","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.iac.2006.05.003_bib50","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.iac.2006.05.003_bib51","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.leukres.2005.08.015","article-title":"A novel K509I mutation of KIT identified in familial mastocytosis\u2014in vitro and in vivo responsiveness to imatinib therapy","volume":"30","author":"Zhang","year":"2006","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.iac.2006.05.003_bib52","first-page":"9","article-title":"Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate","volume":"3","author":"Schaller","year":"2001","journal-title":"MedGenMed"},{"issue":"9317","key":"10.1016\/j.iac.2006.05.003_bib53","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(02)08505-7","article-title":"Treatment of hypereosinophilic syndrome with imatinib mesilate","volume":"359","author":"Gleich","year":"2002","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.iac.2006.05.003_bib54","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0145-2126(02)00046-2","article-title":"Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate","volume":"26","author":"Ault","year":"2002","journal-title":"Leuk Res"},{"issue":"9","key":"10.1016\/j.iac.2006.05.003_bib55","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2002-10-3103","article-title":"Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders","volume":"101","author":"Pardanani","year":"2003","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.iac.2006.05.003_bib56","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2003-01-0081","article-title":"Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.iac.2006.05.003_bib57","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2003-01-0006","article-title":"Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness","volume":"101","author":"Klion","year":"2003","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.iac.2006.05.003_bib58","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2003-07-2274","article-title":"Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities?","volume":"102","author":"Tefferi","year":"2003","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.iac.2006.05.003_bib59","first-page":"871","article-title":"FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia","volume":"89","author":"Tefferi","year":"2004","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.iac.2006.05.003_bib60","doi-asserted-by":"crossref","first-page":"670a","DOI":"10.1182\/blood.V104.11.2441.2441","article-title":"Lineage analysis of the FIP1L1-PDGFRa fusion gene in myeloproliferative hypereosinophilic syndrome","volume":"104","author":"Lemery","year":"2004","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.iac.2006.05.003_bib61","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.iac.2006.05.003_bib62","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","article-title":"FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.iac.2006.05.003_bib63","first-page":"17","article-title":"PKC412\u2014a protein kinase inhibitor with a broad therapeutic potential","volume":"15","author":"Fabbro","year":"2000","journal-title":"Anticancer Drug Res"},{"issue":"5","key":"10.1016\/j.iac.2006.05.003_bib64","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S1535-6108(02)00069-7","article-title":"Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412","volume":"1","author":"Weisberg","year":"2002","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.iac.2006.05.003_bib65","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","article-title":"Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small molecule FLT3 tyrosine kinase inhibitor, PKC412","volume":"105","author":"Stone","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.iac.2006.05.003_bib66","doi-asserted-by":"crossref","first-page":"121a","DOI":"10.1182\/blood.V106.11.404.404","article-title":"Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML","volume":"106","author":"Stone","year":"2005","journal-title":"Blood"},{"issue":"40","key":"10.1016\/j.iac.2006.05.003_bib67","doi-asserted-by":"crossref","first-page":"14479","DOI":"10.1073\/pnas.0404438101","article-title":"PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in the treatment of stem cell myeloproliferative disorder","volume":"101","author":"Chen","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.iac.2006.05.003_bib68","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1535-6108(03)00108-9","article-title":"PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRA-induced myeloproliferative disease","volume":"3","author":"Cools","year":"2003","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.iac.2006.05.003_bib69","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2004-12-4617","article-title":"Activation mutations of human c-Kit resistant to imatinib are sensitive to the tyrosine kinase inhibitor PKC412","volume":"106","author":"Growney","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.iac.2006.05.003_bib70","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.iac.2006.05.003_bib71","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1038\/sj.onc.1206587","article-title":"Signal transduction by several KIT juxtamembrane domain mutations","volume":"22","author":"Casteran","year":"2003","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.iac.2006.05.003_bib72","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1182\/blood.V97.11.3559","article-title":"Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit mediated cytokine-independent survival and proliferation in human leukemia cells","volume":"97","author":"Ning","year":"2001","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.iac.2006.05.003_bib73","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","article-title":"PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison of AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects","volume":"107","author":"Gleixner","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.iac.2006.05.003_bib74","doi-asserted-by":"crossref","first-page":"981a","DOI":"10.1182\/blood.V106.11.3515.3515","article-title":"Detection of activated STAT5 in neoplastic mast cells in patients with systemic mastocytosis: role of c-kit D816V","volume":"106","author":"Sonneck","year":"2005","journal-title":"Blood"},{"issue":"5682","key":"10.1016\/j.iac.2006.05.003_bib75","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overridng imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.iac.2006.05.003_bib76","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in the majority of patients with systemic mastocytosis","volume":"108","author":"Shah","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.iac.2006.05.003_bib77","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies","volume":"66","author":"Schittenhelm","year":"2006","journal-title":"Cancer Res"},{"issue":"5486","key":"10.1016\/j.iac.2006.05.003_bib78","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.iac.2006.05.003_bib79","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)","volume":"62","author":"Nagar","year":"2002","journal-title":"Cancer Res"},{"issue":"34","key":"10.1016\/j.iac.2006.05.003_bib80","doi-asserted-by":"crossref","first-page":"31461","DOI":"10.1074\/jbc.C300186200","article-title":"Structure of a c-kit product complex reveals the basis for kinase transactivation","volume":"278","author":"Mol","year":"2003","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.iac.2006.05.003_bib81","first-page":"639","article-title":"Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors","volume":"7","author":"Mol","year":"2004","journal-title":"Curr Opin Drug Discov Dev"},{"issue":"30","key":"10.1016\/j.iac.2006.05.003_bib82","doi-asserted-by":"crossref","first-page":"31655","DOI":"10.1074\/jbc.M403319200","article-title":"Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase","volume":"279","author":"Mol","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.iac.2006.05.003_bib83","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/asheducation-2005.1.183","article-title":"Loss of response to imatinib: mechanisms and management","author":"Shah","year":"2005","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"2","key":"10.1016\/j.iac.2006.05.003_bib84","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant bcr-abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.iac.2006.05.003_bib85","doi-asserted-by":"crossref","first-page":"985a","DOI":"10.1182\/blood.V106.11.3528.3528","article-title":"Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit","volume":"106","author":"Verstovsek","year":"2005","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.iac.2006.05.003_bib86","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/sj.leu.2403887","article-title":"The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107","volume":"19","author":"Von Bubnoff","year":"2005","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.iac.2006.05.003_bib87","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2004-12-4771","article-title":"In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit","volume":"106","author":"Corbin","year":"2005","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.iac.2006.05.003_bib88","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1182\/blood-2004-06-2189","article-title":"Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970","volume":"104","author":"Corbin","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.iac.2006.05.003_bib89","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1182\/blood-2001-12-0350","article-title":"Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors","volume":"100","author":"Liao","year":"2002","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.iac.2006.05.003_bib90","doi-asserted-by":"crossref","first-page":"11011","DOI":"10.1073\/pnas.0504952102","article-title":"Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases","volume":"102","author":"Carter","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1016\/j.iac.2006.05.003_bib91","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1158\/1535-7163.MCT-05-0114","article-title":"Temporal quantitation of mutant Kit tyrosine kinase signaling attenuated by a novel thiophene kinase inhibitor OSI-930","volume":"4","author":"Petti","year":"2005","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.iac.2006.05.003_bib92","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1158\/0008-5472.CAN-05-2873","article-title":"OSI-930: a novel selective inhibitor of kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models","volume":"66","author":"Garton","year":"2006","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.iac.2006.05.003_bib93","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1182\/blood.V98.3.880","article-title":"Association of the Q576R polymorphism in the interleukin-4 receptor alpha chain with indolent mastocytosis limited to the skin","volume":"98","author":"Daley","year":"2001","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.iac.2006.05.003_bib94","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/01.pas.0000138181.89743.7b","article-title":"CD25 indicates the neoplastic phenotype of mast cells\u2014a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens","volume":"28","author":"Sotlar","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.iac.2006.05.003_bib95","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1586\/14737140.5.1.33","article-title":"Denileukin diftitox: a concise clinical review","volume":"5","author":"Eklund","year":"2005","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"10.1016\/j.iac.2006.05.003_bib96","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2003-07-2477","article-title":"17-Allyamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells","volume":"103","author":"Fumo","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.iac.2006.05.003_bib97","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood-2004-08-3247","article-title":"A novel NF-\u03baB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors","volume":"105","author":"Tanaka","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.iac.2006.05.003_bib98","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/(SICI)1096-8652(199903)60:3<191::AID-AJH4>3.0.CO;2-Y","article-title":"Expression of bcl-2 by human bone marrow mast cells and its overexpression in mast cell leukemia","volume":"60","author":"Cerver\u00f3","year":"1999","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.iac.2006.05.003_bib99","doi-asserted-by":"crossref","first-page":"304b","DOI":"10.1182\/blood.V104.11.4885.4885","article-title":"CD52 is expressed on human mast cells and is a therapeutic target for the anti-CD52 monoclonal antibody Campath-1H in Waldenstrom's macroglobulinemia and mast cell disorders","volume":"104","author":"Santos","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.iac.2006.05.003_bib100","doi-asserted-by":"crossref","first-page":"983a","DOI":"10.1182\/blood.V106.11.3521.3521","article-title":"Heme-oxygenase-1 (HO-1): a novel kit D816V-dependent target in neoplastic human mast cells (HMC-1)","volume":"106","author":"Kondo","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.iac.2006.05.003_bib101","doi-asserted-by":"crossref","first-page":"982a","DOI":"10.1182\/blood.V106.11.3518.3518","article-title":"Inhibition of growth of neoplastic mast cells by CD44 mAb A3D8 is associated with G1 cell cycle arrest and apoptosis","volume":"106","author":"Boehm","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.iac.2006.05.003_bib102","doi-asserted-by":"crossref","first-page":"982a","DOI":"10.1182\/blood.V106.11.3516.3516","article-title":"Identification of Mcl-1 as a novel target in neoplastic mast cells and demonstration of cooperative growth-inhibitory effects of mcl-1 antisense oligonucleotides, PKC412, and AMN107","volume":"106","author":"Aichberger","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.iac.2006.05.003_bib103","doi-asserted-by":"crossref","first-page":"666a","DOI":"10.1182\/blood.V104.11.2426.2426","article-title":"Murine model of aggressive systemic mastocytosis: a disease caused by oncogenic kit","volume":"104","author":"Demehri","year":"2004","journal-title":"Blood"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856106000506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856106000506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T17:48:18Z","timestamp":1587318498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856106000506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":103,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S0889856106000506"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2006.05.003","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}